The results of phase III multicenter open randomized controlled study REM-Chol-III-16 in patients with intrahepatic cholestasis syndrome caused by chronic diffuse liver diseases

Author:

Stel'makh Viktoriia V.ORCID,Kovalenko Aleksey L.ORCID,Popova Veronika B.ORCID,Uspenskiy Yury P.ORCID,Morozov Viacheslav G.ORCID,Belikova Tatiana N.ORCID,Rafalskiy Vladimir V.ORCID,Antonova Elizaveta A.ORCID

Abstract

Aim. To assess the safety and efficacy of Remaxol, solution for infusion, compared with parenteral form of S-adenosyl-L-methionine, in the treatment of patients with intrahepatic cholestasis syndrome accompanying chronic diffuse liver diseases of various etiology. Materials and methods. In a multicenter open-label comparative study of the safety and efficacy of Remaxol (inosine + meglumine + methionine + nicotinamide + succinic acid) 317 patients aged 18 to 65 years were randomized into 2 groups: patients of the experimental group (n=168) received intravenous Remaxol, solution for infusion, 400 ml, and patients of the control group (n=149) Heptral (S-adenosyl-L-methionine) 800 mg. The duration of treatment was 10 days. The primary efficacy endpoint was the proportion of patients who responded to therapy, as demonstrated by dynamics of laboratory parameters of liver functional status: decrease in gamma glutamyl transpeptidase level by 40%, and/or alkaline phosphatase level by 30%, and/or decrease total bilirubin level by 30% from baseline by the end of the treatment course. Results. The proportion of responders was 51% in the Remaxol group vs. 44.9% in the Heptral group (p=0.303); the lower limit of the one-sided 95% confidence interval for the difference in the proportions of responders was -4.01%, which exceeds the non-inferiority margin pre-defined by the study protocol, thus, the non-inferiority hypothesis was proven, i.e. Remaxol at a dose of 400 ml/day demonstrates similar efficacy to Heptral at a dose of 800 mg/day in patients with intrahepatic cholestasis syndrome associated with chronic diffuse liver diseases. Similar positive trends in the levels of transaminases, total bilirubin and the severity of pruritus were revealed in both treatment groups. We did not reveal statistically significant between-group differences in the frequency of adverse events definitely related to the study treatment. Conclusion. Administration of Remaxol as a part of the pathogenetic therapy of patients with intrahepatic cholestasis syndrome who need hepatoprotection is justified.

Publisher

Consilium Medicum

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,History,Family Practice

Reference17 articles.

1. Ивашкин В.Т., Широкова Е.Н., Маевская М.В., и др. Клинические рекомендации по диагностике и лечению холестаза. М., 2013 [Ivashkin VT, Shirokova EN, Mayevskaya MV, et al. Klinicheskie rekomendatsii po diagnostike i lecheniiu kholestaza. Moscow, 2013 (in Russian)].

2. Подымова С.Д. Болезни печени. М.: Медицина, 2005 [Podymova SD. Bolezni pecheni. Moscow: Medicina, 2005 (in Russian)].

3. Голованова Е.В., Петраков А.В., Носкова К.К. Внутрипеченочный холестаз при хронических заболеваниях печени. Экспериментальная и клиническая гастроэнтерология. 2011;2:58-67 [Golovanova EV, Petrakov AV, Noskova KK. Intrahepatic cholestasis in chronic liver diseases. Eksperimental'naya i klinicheskaya gastroenterologiya. 2011; 2: 58-67 (in Russian)].

4. Минушкин О.Н. Лечение основных проявлений болезней печени. Клиническая фармакология и терапия. 1996;1:4-8 [Minushkin ON. Treatment of the main manifestations of liver disease. Klinicheskaya farmakologiya i terapiya. 1996;1:4-8 (in Russian)].

5. Успенский Ю.П., Барышникова Н.В., Фоминых Ю.А. Опыт применения урсодезоксихолевой кислоты у пациентов с гастроэнтерологическими кластерами метаболического синдрома, ассоциированными с явлениями холестаза. Медицина: теория и практика. 2018;3(1):96-7 [Uspensky YuP., Baryshnikova NV, Fominykh YuA. Experience of using ursodeoxycholic acid in patients with gastroenterological clusters of metabolic syndrome associated with cholestasis. Meditsina: teoriya i praktika. 2018;3(1):96-7 (in Russian)]

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3